Evidence map›Paper›PMID 10928968›Full record

ArticleBritish journal of pharmacology2000

The P(2)-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus.

K M Jenkinson, J J Reid

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Intrinsic inhibitory innervation of the stomach.British journal of pharmacology · 2005
    Article
  7. Article
  8. Inhibitory pathways in the circular muscle of rat jejunum.British journal of pharmacology · 2004
    Article
  9. Purine and pyrimidine (P2) receptors as drug targets.Journal of medicinal chemistry · 2002
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

K M JenkinsonDepartment of Anatomy and Cell Biology, University of Melbourne, Victoria 3010, Australia. KJenkinson@anatomy.unimelb.edu.au
J J Reid
The Royal Melbourne Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The P(2)-purinoceptor antagonist, suramin, was used to investigate the possible involvement of adenosine 5'-triphosphate (ATP) in the inhibitory non-adrenergic non-cholinergic (NANC) innervation of the rat gastric fundus. ATP (1-30 microM) produced biphasic responses consisting of concentration-dependent relaxations followed by concentration-dependent contractions. Suramin (200 microM) significantly reduced relaxations and abolished contractions to ATP. Under NANC conditions, electrical field stimulation (EFS) induced frequency-dependent relaxations. Suramin (200 microM) and the peptidase alpha-chymotrypsin (1 u ml(-1)) had the same effects on EFS-induced relaxations: their duration was reduced, but their magnitude was unaffected. Cumulative relaxations to vasoactive intestinal peptide (VIP; 0.1-100 nM), and to the VIP analogue pituitary adenylate cyclase activating peptide 1-27 (PACAP; 0.2-100 nM), were almost completely abolished by alpha-chymotrypsin (1 u ml(-1)), and were inhibited by suramin (3-200 microM) in an apparently competitive manner. Schild plot analysis indicated that suramin had pA(2) values of 5.1+/-0.2 (Hill slope=0.9+/-0.2) and 5.6+/-0.1 (Hill slope=1.0+/-0.1), against VIP and PACAP, respectively. Concentration-dependent relaxations to nitric oxide (1-30 microM) and cumulative relaxations to isoprenaline (0.1-300 nM) were not affected by suramin (200 microM). No conclusions can be made regarding the possible involvement of ATP in EFS-induced NANC relaxations. The results suggest that suramin acts as a competitive antagonist at VIP receptors in the rat gastric fundus.

Indexed as

Purinergic P2 Receptor AntagonistsAdenosine TriphosphateAdrenergic beta-AgonistsAnimalsBinding, CompetitiveDrug InteractionsGastric FundusIn Vitro TechniquesIsoproterenolMaleMuscle RelaxationNeuropeptidesNitric OxideNitroprussidePituitary Adenylate Cyclase-Activating PolypeptideRatsAdcyap1 protein, ratAdenosine TriphosphateAdrenergic beta-AgonistsIsoproterenolNeuropeptidesNitric OxideNitroprussidePituitary Adenylate Cyclase-Activating PolypeptidePurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Receptors, Vasoactive Intestinal PeptideSuraminVasoactive Intestinal PeptideVasodilator Agents

Identifiers

PMID10928968
PMCPMC1572236
OpenAlexW1967449228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.